Renin, prorenin and the kidney: A new chapter in an old saga

Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Yuki Kaneshiro, Hiroshi Itoh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The binding of prorenin to the (pro)renin receptor triggers 2 major pathways: a nonproteolytic conformational change in prorenin to its active form (angiotensin II-dependent pathway) and an intracellular pathway via the (pro)renin receptor itself (angiotensin II-independent pathway). In diabetic animals, an increased plasma prorenin level not only causes the generation of angiotensin II via the angiotensin II-dependent pathway, it also stimulates the (pro)renin receptor's own intracellular signaling pathway in a manner that is independent of the generated angiotensin II. Thus, the administration of a "handle" region peptide (HRP), which acts as a decoy peptide and competitively inhibits the binding of prorenin to the (pro)renin receptor, has a beneficial effect in the kidneys of diabetic animals with low plasma renin levels. However, the benefits of HRP are slightly reduced in animal models of essential hypertension with relatively high plasma renin levels, and these benefits disappear altogether in animal models of hypertension with extremely high plasma renin levels. Thus, in the kidneys of animal models of diabetes and/or hypertension, both renin and prorenin competitively bind to the (pro)renin receptor and contribute to the pathophysiology of nephropathy. Consequently, renin, prorenin and the (pro) renin receptor may be important therapeutic targets for the prevention and regression of nephropathy in patients with diabetes and/or hypertension.

Original languageEnglish
Pages (from-to)306-311
Number of pages6
JournalJournal of Nephrology
Volume22
Issue number3
Publication statusPublished - 2009

Fingerprint

Renin
Kidney
Angiotensin II
Animal Models
Hypertension
Peptides
prorenin receptor

Keywords

  • (Pro)renin receptor
  • Aliskiren
  • Angiotensin
  • Handle region peptide
  • Mitogen-activated protein kinases

ASJC Scopus subject areas

  • Nephrology

Cite this

Ichihara, A., Sakoda, M., Kurauchi-Mito, A., Kaneshiro, Y., & Itoh, H. (2009). Renin, prorenin and the kidney: A new chapter in an old saga. Journal of Nephrology, 22(3), 306-311.

Renin, prorenin and the kidney : A new chapter in an old saga. / Ichihara, Atsuhiro; Sakoda, Mariyo; Kurauchi-Mito, Asako; Kaneshiro, Yuki; Itoh, Hiroshi.

In: Journal of Nephrology, Vol. 22, No. 3, 2009, p. 306-311.

Research output: Contribution to journalArticle

Ichihara, A, Sakoda, M, Kurauchi-Mito, A, Kaneshiro, Y & Itoh, H 2009, 'Renin, prorenin and the kidney: A new chapter in an old saga', Journal of Nephrology, vol. 22, no. 3, pp. 306-311.
Ichihara A, Sakoda M, Kurauchi-Mito A, Kaneshiro Y, Itoh H. Renin, prorenin and the kidney: A new chapter in an old saga. Journal of Nephrology. 2009;22(3):306-311.
Ichihara, Atsuhiro ; Sakoda, Mariyo ; Kurauchi-Mito, Asako ; Kaneshiro, Yuki ; Itoh, Hiroshi. / Renin, prorenin and the kidney : A new chapter in an old saga. In: Journal of Nephrology. 2009 ; Vol. 22, No. 3. pp. 306-311.
@article{66ee259096714736b3d7a27d28f3e12a,
title = "Renin, prorenin and the kidney: A new chapter in an old saga",
abstract = "The binding of prorenin to the (pro)renin receptor triggers 2 major pathways: a nonproteolytic conformational change in prorenin to its active form (angiotensin II-dependent pathway) and an intracellular pathway via the (pro)renin receptor itself (angiotensin II-independent pathway). In diabetic animals, an increased plasma prorenin level not only causes the generation of angiotensin II via the angiotensin II-dependent pathway, it also stimulates the (pro)renin receptor's own intracellular signaling pathway in a manner that is independent of the generated angiotensin II. Thus, the administration of a {"}handle{"} region peptide (HRP), which acts as a decoy peptide and competitively inhibits the binding of prorenin to the (pro)renin receptor, has a beneficial effect in the kidneys of diabetic animals with low plasma renin levels. However, the benefits of HRP are slightly reduced in animal models of essential hypertension with relatively high plasma renin levels, and these benefits disappear altogether in animal models of hypertension with extremely high plasma renin levels. Thus, in the kidneys of animal models of diabetes and/or hypertension, both renin and prorenin competitively bind to the (pro)renin receptor and contribute to the pathophysiology of nephropathy. Consequently, renin, prorenin and the (pro) renin receptor may be important therapeutic targets for the prevention and regression of nephropathy in patients with diabetes and/or hypertension.",
keywords = "(Pro)renin receptor, Aliskiren, Angiotensin, Handle region peptide, Mitogen-activated protein kinases",
author = "Atsuhiro Ichihara and Mariyo Sakoda and Asako Kurauchi-Mito and Yuki Kaneshiro and Hiroshi Itoh",
year = "2009",
language = "English",
volume = "22",
pages = "306--311",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",
number = "3",

}

TY - JOUR

T1 - Renin, prorenin and the kidney

T2 - A new chapter in an old saga

AU - Ichihara, Atsuhiro

AU - Sakoda, Mariyo

AU - Kurauchi-Mito, Asako

AU - Kaneshiro, Yuki

AU - Itoh, Hiroshi

PY - 2009

Y1 - 2009

N2 - The binding of prorenin to the (pro)renin receptor triggers 2 major pathways: a nonproteolytic conformational change in prorenin to its active form (angiotensin II-dependent pathway) and an intracellular pathway via the (pro)renin receptor itself (angiotensin II-independent pathway). In diabetic animals, an increased plasma prorenin level not only causes the generation of angiotensin II via the angiotensin II-dependent pathway, it also stimulates the (pro)renin receptor's own intracellular signaling pathway in a manner that is independent of the generated angiotensin II. Thus, the administration of a "handle" region peptide (HRP), which acts as a decoy peptide and competitively inhibits the binding of prorenin to the (pro)renin receptor, has a beneficial effect in the kidneys of diabetic animals with low plasma renin levels. However, the benefits of HRP are slightly reduced in animal models of essential hypertension with relatively high plasma renin levels, and these benefits disappear altogether in animal models of hypertension with extremely high plasma renin levels. Thus, in the kidneys of animal models of diabetes and/or hypertension, both renin and prorenin competitively bind to the (pro)renin receptor and contribute to the pathophysiology of nephropathy. Consequently, renin, prorenin and the (pro) renin receptor may be important therapeutic targets for the prevention and regression of nephropathy in patients with diabetes and/or hypertension.

AB - The binding of prorenin to the (pro)renin receptor triggers 2 major pathways: a nonproteolytic conformational change in prorenin to its active form (angiotensin II-dependent pathway) and an intracellular pathway via the (pro)renin receptor itself (angiotensin II-independent pathway). In diabetic animals, an increased plasma prorenin level not only causes the generation of angiotensin II via the angiotensin II-dependent pathway, it also stimulates the (pro)renin receptor's own intracellular signaling pathway in a manner that is independent of the generated angiotensin II. Thus, the administration of a "handle" region peptide (HRP), which acts as a decoy peptide and competitively inhibits the binding of prorenin to the (pro)renin receptor, has a beneficial effect in the kidneys of diabetic animals with low plasma renin levels. However, the benefits of HRP are slightly reduced in animal models of essential hypertension with relatively high plasma renin levels, and these benefits disappear altogether in animal models of hypertension with extremely high plasma renin levels. Thus, in the kidneys of animal models of diabetes and/or hypertension, both renin and prorenin competitively bind to the (pro)renin receptor and contribute to the pathophysiology of nephropathy. Consequently, renin, prorenin and the (pro) renin receptor may be important therapeutic targets for the prevention and regression of nephropathy in patients with diabetes and/or hypertension.

KW - (Pro)renin receptor

KW - Aliskiren

KW - Angiotensin

KW - Handle region peptide

KW - Mitogen-activated protein kinases

UR - http://www.scopus.com/inward/record.url?scp=69449099438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449099438&partnerID=8YFLogxK

M3 - Article

C2 - 19557706

AN - SCOPUS:69449099438

VL - 22

SP - 306

EP - 311

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 3

ER -